Nevro resumed with an Equal Weight at Wells Fargo

Wells Fargo resumed coverage of Nevro (NVRO) with an Equal Weight rating and $5 price target Wells believes Nevro is comfortable with consensus implying a return to year over year sales growth in the second half of 2025, though the firm does not see upside to Street estimates, the analyst tells investors in a research note. Easier y/y comps, lessened competitive trialing, AdaptivAI ramp, continued healthy growth in painful diabetic neuropathy, adding new sales territories, and Vyrsa ramping could support 2025 growth, the firm says.